Pharmacokinetic basis for dosing high‐dose methotrexate in infants and young children with malignant brain tumors

AIMS: No population pharmacokinetic studies of high-dose methotrexate (HDMTX) have been conducted in infants with brain tumours, which are a vulnerable population. The aim of this study was to evaluate HDMTX disposition in these children to provide a rational basis for MTX dosing. METHODS: Patients received 4 monthly courses of HDMTX (5 g/m(2) or 2.5 g/m(2) for infants aged